Drug used in Donald Trump’s treatment in India; The price is staggering …

Mumbai : Pharmaceutical company Roche India on Monday announced the launch of an anti-corona antibody cocktail in the Indian market. The antibody cocktail is called Casirivimab and Imdevimab and is priced at Rs 59,750 per dose. The dose was given to then US President Donald Trump when he contracted coronary heart disease.
Coronavirus vaccine corona vaccine is experienced in young people with ‘these’ symptoms; The CDC issued a warning
Each 1200 mg dose will contain 600 mg Casirivimab and 600 mg Imdevimab. The price of each dose has been fixed at Rs 59,750. The wholesale price of this dose pack will be Rs. 1 lakh 19 thousand 500. Two patients can be treated in each pack, the company said in a statement.
covid vaccine: buy the vaccine wrapped in policy! Pfizer, rejection of modern states; In contact with the Central Government
The drug will be launched in the Indian market by Cipla and will be available to all in mid-June. The first batch of the drug is available in India, while the second batch will be available by mid-June. One lakh packs have been made available in India, which can treat about two lakh patients, a joint statement issued by Cipla and Roche said.

The drug will be available at leading hospitals and Kovid centers in India. The drug was recently given emergency clearance by the Central Drug Control Agency (CDSCO). The drug had previously been approved in Europe and the United States.
covid vaccine: States will get 48 lakh doses of corona vaccine in 3 days
Roche is determined to cope with the crisis caused by the second wave of Corona and to save precious lives. This cocktail will eliminate the need to go to the hospital and will reduce the stress on the health system. V Simpson, managing director and CEO of Roche India, commented that it would help to treat the patient before his condition became critical.

Antibody cocktails can be used for patients with moderate symptoms. This dose can be taken by patients above 12 years of age (minimum weight of 40 kg required). The company says that taking this dose while having severe symptoms of coronary heart disease does not reduce oxygen levels. This drug reduces the risk of hospitalization and death by up to 70 percent.